Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 7/20 | 0.64 |
| ▸ | ERN1 | O75460 | 3/20 | 0.62 |
| ▸ | DHODH | Q02127 | 3/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.56 |
| ▸ | CCND1 | P24385 | 1/20 | 0.56 |
| ▸ | CCNC | P24863 | 1/20 | 0.56 |
| ▸ | CDK8 | P49336 | 1/20 | 0.56 |
| ▸ | CDK7 | P50613 | 1/20 | 0.56 |
| ▸ | CDK9 | P50750 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31422694 | 1.00 | PARP1 (0.64) | PARP1ERN1DHODHTSHRPOLB | |
| SCHEMBL6999225 | 0.98 | DHODH (0.63) | PARP1ERN1DHODHTSHRPOLB | |
| SCHEMBL29788172 | 0.93 | DHODH (0.70) | PARP1ERN1DHODHTSHRPOLB | |
| SCHEMBL43553 | 0.93 | DHODH (0.70) | PARP1ERN1DHODHTSHRPOLB | |
| SCHEMBL2589651 | 0.91 | ERN1 (0.60) | PARP1ERN1DHODHTSHRPOLB | |
| Hydrochloric Acid SCHEMBL3973404 | 0.91 | DHODH (0.68) | PARP1ERN1DHODHTSHRPOLB | |
| SCHEMBL29941476 | 0.91 | DHODH (0.68) | PARP1ERN1DHODHTSHRPOLB | |
| Hydrochloric Acid SCHEMBL30628442 | 0.91 | DHODH (0.68) | PARP1ERN1DHODHTSHRPOLB | |
| SCHEMBL18397582 | 0.91 | KMO (0.70) | PARP1ERN1DHODHTSHRPOLB | |
| Bromide SCHEMBL30159854 | 0.91 | DHODH (0.68) | PARP1ERN1DHODHTSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016004093-A2 | THERAPEUTIC COMPOSITIONS INCLUDING GALECTIN-3 INHIBITORS AND USES THEREOF | STEALTH BIOTHERAPEUTICS CORP (MC) | 2016-01-07 | — | — | WO | disclosed |
| EP-1751171-B1 | NOVEL GALACTOSIDE INHIBITORS OF GALECTINS | FORSKARPATENT I SYD AB (SE) | 2011-09-21 | — | — | EP | disclosed |
| US-7638623-B2 | Galactoside inhibitors of galectins | FORSKARPATENT I SYD AB (SE) | 2009-12-29 | — | — | US | disclosed |
| US-20070185039-A1 | NOVEL GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (SE) | 2007-08-09 | — | — | US | disclosed |
| US-5064832-A | Bipyrimidine Compounds, Antitumor Agents | CIBA-GEIGY CORPORATION (US) | 1991-11-12 | — | — | US | disclosed |
| US-4968804-A | Bipyridine compounds | CIBA-GEIGY CORPORATION (US) | 1990-11-06 | — | — | US | disclosed |
| EP-0350448-A1 | Biaryl compounds | CIBA-GEIGY AG (CH) | 1990-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185039-A1 | NOVEL GALACTOSIDE INHIBITORS OF GALECTINS | LGALS3, LGALS1, LGALS2 | PARP1 1590/4885ERN1 1829/4885DHODH 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.